Liaoning Cheng Da Co., Ltd. (SHA:600739)
9.78
0.00 (0.00%)
Nov 17, 2026, 3:00 PM CST
Liaoning Cheng Da Revenue
Liaoning Cheng Da had revenue of 1.97B CNY in the quarter ending September 30, 2026, a decrease of -25.22%. This brings the company's total for the last twelve months to 8.55B, down -16.38% year-over-year. In the year 2025, Liaoning Cheng Da had annual revenue of 9.90B, down -8.06%. That makes Liaoning Cheng Da the 6,622nd largest company in the world by revenue and 921st in China.
Revenue (ttm)
8.55B
Revenue Growth
-16.38%
P/S Ratio
1.74
Revenue / Employee
3.12M
Employees
2,740
Market Cap
14.89B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Liaoning Cheng Da breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.90B | -868.14M | -8.06% |
| Dec 31, 2024 | 10.77B | -12.83M | -0.12% |
| Dec 31, 2023 | 10.78B | -3.78B | -25.97% |
| Dec 31, 2022 | 14.56B | -3.81B | -20.73% |
| Dec 31, 2021 | 18.37B | 1.43B | 8.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Pharmaceuticals Holding | 291.47B |
| Jointown Pharmaceutical Group | 171.51B |
| C.Q. Pharmaceutical Holding | 80.51B |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company | 78.13B |
| China National Accord Medicines Corporation | 73.36B |
| China National Medicines Corporation | 53.69B |
| China Meheco Group | 34.46B |
| Guangxi LiuYao Group | 21.31B |